CPT 11900 & 11901: Intralesional Injection Coding Guide

Intralesional injections represent some of the highest-volume minor procedures in medical dermatology, yet they routinely trigger post-payment audits, line-item denials, and uncaptured drug revenue. Payers frequently scrutinize these claims because providers miscount treated lesions, fail to document exact drug wastage, or attach Modifier 25 to Evaluation and Management (E/M) visits without documenting a distinct clinical service. Resolving these recurring errors requires tight alignment between clinical documentation, procedural coding, and HCPCS Level II drug unit calculations.

Defining the CPT Code Hierarchy for Intralesional Injections

The Current Procedural Terminology (CPT) code set provides two distinct codes for intralesional injections based strictly on the number of discrete lesions treated during a single clinical encounter:

• CPT 11900: Injection, intralesional; up to and including 7 lesions.
• CPT 11901: Injection, intralesional; more than 7 lesions.

These codes are defined by total lesion count, not by the number of needle passes, puncture sites, or anatomical distribution. If a clinician injects four distinct keloids on the chest and two hypertrophic scars on the shoulder, the correct procedural code is 11900 because the total volume across all sites is six lesions.

CPT 11900 and 11901 are mutually exclusive under National Correct Coding Initiative (NCCI) edit tables. Billing teams must never submit both codes on the same date of service. If a patient receives intralesional therapy across ten lesions, the claim should contain a single line item for CPT 11901 billed with one unit of service—never CPT 11900 plus CPT 11901, and never CPT 11900 billed with multiple units.

Calculating HCPCS Drug Units and Managing Wastage

Intralesional injection codes describe the procedural work of the injection alone; they do not include the cost of the injected therapeutic agent. Practices must bill the medication separately using the corresponding HCPCS Level II code. The most common agent injected in outpatient dermatology is triamcinolone acetonide (TAC), represented by HCPCS code J3301 (*Injection, triamcinolone acetonide, not otherwise specified, 10 mg*).

A common source of billing error is misinterpreting the billing unit definition on the HCPCS code. For J3301, one billing unit equals 10 mg of medication:

• Administering 10 mg (e.g., 1.0 mL of TAC-10 or 0.25 mL of TAC-40) equals 1 unit.
• Administering 20 mg (e.g., 0.5 mL of TAC-40) equals 2 units.
• Administering 5 mg (e.g., 0.5 mL of TAC-10) still requires billing 1 unit, as standard payer rounding rules dictate rounding up to the nearest whole billing unit for administered quantities below one full unit.

When utilizing single-dose vials, practices must also capture and report discarded medication correctly. Medicare MACs and commercial payers require the JW modifier (*Drug amount discarded/not administered to any patient*) to identify discarded drug from single-use containers, reported on a separate claim line from the administered portion. Effective across all Medicare claims, the JZ modifier (*Zero drug amount discarded/not administered to any patient*) must be appended when there is zero wastage from a single-dose vial. In multidose vial scenarios, practices may only bill for the exact amount administered; drug wastage from multidose vials cannot be reimbursed.

Integrating drug unit calculations into standard dermatology procedure billing workflows ensures that procedural fees and pharmaceutical supply costs are fully captured on initial claim submission.

Same-Day E/M and Modifier 25 Interactions

Intralesional injections carry a 0-day global surgical period. Under Medicare NCCI guidelines, standard pre-procedural assessment (evaluating the lesion, obtaining consent, cleansing the skin) and post-procedural care (applying pressure or dressings) are bundled directly into the reimbursement for CPT 11900 and 11901.

To bill an E/M service (CPT 99202–99215) on the same date of service, the documentation must demonstrate a significant, separately identifiable medical service, supported by Modifier 25:

• Separately Identifiable Scenario: A patient presents for evaluation of a new generalized rash (e.g., guttate psoriasis) requiring medical history, examination, and a new topical prescription. During the same encounter, the provider evaluates and injects an established recalcitrant keloid with triamcinolone. The E/M service is distinct from the procedure and supports Modifier 25.
• Non-Billable E/M Scenario: A patient returns for a planned, serial intralesional injection for alopecia areata. The provider checks the scalp, confirms the sites have not fully regrown, and administers the injections. The assessment performed is standard procedural pre-work. Billing an E/M service with Modifier 25 in this scenario will not withstand audit scrutiny.

When an E/M service is supported, the clinical note must segregate the medical decision-making related to the separate condition from the procedural notes detailing the injection.

Actionable Documentation and Workflow Controls

To eliminate denials and prevent compliance recoupments on intralesional injection encounters, implement the following operational controls across your clinical and billing teams:

• Standardize Procedure Note Templates: Require clinicians to explicitly enumerate every treated lesion by anatomical site in the electronic health record (EHR) rather than using generalized phrases like "injected multiple lesions."
• Enforce EHR Smart Form Prompts: Configure procedural EHR templates to capture drug name, concentration (mg/mL), total volume administered (mL), total milligrams administered, vial type (single-dose vs. multidose), and exact discarded volume.
• Automate HCPCS Unit Translation: Establish billing rules within your practice management software that auto-convert recorded milligrams into correct HCPCS units (e.g., converting 40 mg of triamcinolone into 4 units of J3301) to prevent manual calculation mistakes.
• Audit Same-Day Modifier 25 Usage: Institute a weekly pre-claim scrub on all claims containing an E/M code paired with CPT 11900 or 11901 to verify that the chart note contains a distinct chief complaint, interval history, and separate medical decision-making.
• Match Diagnostic Codes to Procedural Lines: Link specific ICD-10 diagnosis codes (e.g., L91.0 for hypertrophic scar/keloid, L63.0–L63.9 for alopecia areata, L40.0 for plaque psoriasis) directly to both the CPT line item and the HCPCS drug line item on the CMS-1500 claim form.

If your practice is experiencing frequent denials on minor surgical claims, unbundling rejections, or audit inquiries regarding same-day office visits, reach out to our team to schedule a comprehensive dermatology claims audit.